Result of AGM

RNS Number : 9242E

Oxford Biomedica PLC

07 June 2012

 



FOR IMMEDIATE RELEASE

OXFORD BIOMEDICA PLC

ANNUAL GENERAL MEETING

Oxford, UK - 7 June 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

·      Resolution 7: to empower the Directors to allot equity securities, pursuant to section 551 of the Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £3,149,585 with a further aggregate nominal amount of £3,149,585 authorised in connection with a rights issue, or where applicable, other proportionate offer;

·      Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;

·      Resolution 9: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolutions passed at the 2012 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (05 June 2012) there were 944,875,557 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes  For	Votes at  Chairman's Discretion	Votes at  other proxy Discretion	Votes Against	Votes  Withheld	Total votes cast	Result
Ordinary resolutions
1	334,190,163	765,212	447,598	878,280	802,841	337,084,094	Passed
2	291,370,322	757,259	447,598	35,830,273	8,678,642	337,084,094	Passed
3	331,941,913	756,295	447,598	2,983,405	954,883	337,084,094	Passed
4	334,468,411	756,295	447,598	446,405	965,385	337,084,094	Passed
5	333,401,900	756,295	447,598	478,823	1,999,478	337,084,094	Passed
6	335,032,894	627,980	447,598	143,561	832,061	337,084,094	Passed
7	330,398,126	659,364	447,598	2,869,269	2,709,737	337,084,094	Passed
Special resolutions
8	334,634,982	652,946	447,598	362,936	985,632	337,084,094	Passed
9	329,424,402	636,549	447,598	5,769,015	806,530	337,084,094	Passed

With regard to Resolution 7, this was taken on a poll called by the Chairman of the Company at the meeting and the results were as follows:

Votes  For	Votes Against	Votes  Withheld	Total votes cast	Result
333,155,858	5,793,459	2,787,570	338,949,317	Passed

The number of votes validly cast in relation to Resolution 7 was 338,949,317 which constitutes 35.87% of the of the issued share capital of the Company.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb.  Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

RAGSSWFDWFESEIM